Cramer's Mad Money - Agnico Eagle's Golden Disappointment (11/2/09)

by: Miriam Metzinger

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday November 2

CEO Sean Boyd, Agnico Eagle Mines (NYSE:AEM)

Cramer was disappointed that his top gold pick reported a 2 cent loss while The Street predicted a 21 cent gain. Agnico Eagle (AEM) also reported lower output and higher production costs. Cramer says the company's bad quarter is another reason to prefer SPDR GoldShares ETF (NYSEARCA:GLD), but he wanted to give Sean Boyd a chance to defend himself and his company. Boyd said the shutting down of one mine for 22 days and another for 7 days was due to startup and commissioning issues that have been settled. He added production costs will return to their low levels and said gold stocks have much stronger, consistent returns than owning gold bullion.

Cramer declined to recommend buying or selling the Agnico Eagle Mines, since he was disappointed by the company's results.

Ford (NYSE:F), 3M (NYSE:MMM), Freeport McMoRan (NYSE:FCX), United Tech (NYSE:UTX), BHP (NYSE:BHP), Kohl's (NYSE:KSS), TJX (NYSE:TJX), Costco (NASDAQ:COST), Denbury Resources (NYSE:DNR), Encore Energy Partners (NYSE:ENP), Stanley Works (NYSE:SWK), Black & Decker (BDK)

Cramer says it is never a good idea to be too bullish or too bearish, but right now, the bears are making too much noise. While it is true that Denbury Resources' (DNR) acquisition of Energy Partners (ENP) is not such a great idea, and Stanley Works' (SWK) bid to purchase Black & Decker (BDK) is an even worse idea, there is a lot to like in the market right now; Ford (F) reported a strong quarter, and orders at 3M (MMM), Freeport (FCX), BHP (BHP) and United Tech (UTX) are up. Bears exaggerated somewhat slow back to school sales, which were actually better than expected, and of course are howling over what they predict will be a dismal holiday season for retail.

Cramer would disregard the excessive bearish sentiment which is the same mentality that encouraged investors to sit on the sidelines and miss the Dow's move from 6,500 to 10,000. “It is possible to be too skeptical,” Cramer said, “and the bears along with the media have taken skepticism of this market to the utmost extremes. Don’t be fooled – There are real positives out there.”

Bristol Myers Squibb (NYSE:BMY), Pfizer (NYSE:PFE)

Cramer has dedicated the week to discussing healthcare companies with cutting edge cancer treatments, and featured Bristol Myers (BMY) and Pfizer (PFE) on Monday. Trading at one time their growth rates, and providing generous dividends, the companies represent "The most conservative ways to play the fight against cancer." Both are down since their earnings reports, and both are trading at a discount. While neither company has a pure play, Bristol Myers and Pfizer have diversified and strong oncology divisions.

Cramer was once a hater of Pfizer, but it is now "one of the most diversified healthcare players out there" since its Wyeth (WYE) buyout, which should expand the company's treatment options. Pfizer has 22 cancer drugs, including Aromasin for breast cancer, Camptoar for colorectal cancer, and its most promising treatment, Stutent, which inhibits bloodflow to tumors. While its cholesterol drug Lipitor is going off patent, Pfizer is expected to continue making acquisitions that will expand its reach.

Bristol Myers has doubled its pipeline since the Medarex acquisition in October 2007, and owns an 83% stake in Mead Johnson Nutrition (NYSE:MJN). The company has $9 billion for more acquisitions which should offset losses when its cardiovascular drug Plavix goes off patent in 2012. Currently Bristol Myers has a Phase III drug for metastic melanoma, Erbitux for colorectal, head and neck cancer, Sprycel for Leukemia, Ixempra for breast cancer and Taxol for breast, lung and ovarian cancer. Sprycel is the fastest grower of these treatments, and its sales have jumped 40% year-over-year.

Cramer says Bristol Myers and Pfizer are great investments for everyone but very young investors who may want a bit more risk.

CEO Interview: Martin Franklin, Jarden (NYSE:JAH)

Jarden (JAH) might not be a household name, but its brands, which include Sunbeam, Oster, Rival and Mr. Coffee, are. The company's eclectic assortment of brands might seem confusing, but its diversity is paying off. The company beat earnings by 12 cents a share, is flush with cash and has growing margins. The stock has had a 138% rise over the last year, and Cramer asked if Jarden will continue its trend higher. Martin Franklin said the company intends to expand its brands to reach younger and older consumers and to extend its international reach. He added the company will continue to pay out its dividend and will use profits to fund further growth.


Seeking Alpha publishes a summary of Jim Cramer's stock picks every day including: Mad Money Recap, Lightning Round and his Stop Trading! Picks.

Get Cramer's Picks by email-- it's free and takes only a few seconds to sign up.

Seeking Alpha is not affiliated with Jim Cramer, CNBC or